12h
GlobalData on MSNAnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trialAnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...
Recognition of telehealth as an effective strategy for delivering treatment for substance use disorder (SUD) has raised hopes for improving access to this treatment in settings with limited ...
15h
Investor's Business Daily on MSNAnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis TreatmentAnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
ANSWER: Both RA and MCTD are rheumatologic diseases that affect many systems of the body. MCTD is often considered an overlap ...
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.
The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...
My husband, who is 71, has been having some short-term memory problems over the past two years. We recently saw his primary doctor, who asked him some questions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results